Chatbot help for lung cancer patients on targeted therapy
Part of Cancer, Lungs & breathing clinical trials.
This study tests if a LINE chatbot can help you manage side effects from your EGFR-TKI targeted therapy. If you have advanced lung cancer and are taking a pill like gefitinib or osimertinib, this chatbot might help you track symptoms and communicate with your care team.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced lung cancer (stage IIIB to IVB) that cannot be removed by surgery, or your cancer has come back for the first time.
- You are taking one of these targeted therapy pills: gefitinib, erlotinib, afatinib, dacomitinib, or osimertinib.
- You can take care of yourself day-to-day (ECOG score 2 or better).
- You can read and understand Chinese, and you can use a smartphone with the LINE app.
- You are not being treated for another cancer and are not receiving any other cancer treatments right now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether adding OBI-833/OBI-821 to the standard targeted pill erlotinib works better for some people with EGFR-mutated lung cancer. It may help shrink tumors that already started responding to erlotinib.
This trial tests a new way to choose your next treatment by growing a mini version of your tumor (an organoid) in a lab and seeing which drugs kill it best. It is for people with drug-resistant non-small cell lung cancer who have already tried at least two standard treatments.
This study uses a mobile internet platform (WeChat) to check on how patients are doing after lung cancer surgery. It aims to improve your recovery and quality of life by collecting updates on your health.
This trial studies how Traditional Chinese Medicine (TCM) patterns relate to the effectiveness of targeted pills (EGFR-TKIs) in lung cancer. It is for people with EGFR-mutated non-small cell lung cancer who are about to start or are already on this type of treatment.
This study tests a smartphone-based program to help people with advanced lung cancer manage their symptoms and daily life. The program uses WhatsApp or WeChat to provide support and aims to improve quality of life.
This study tests a smartphone app designed to help lung cancer patients track and manage side effects while receiving combination drug therapy at home. The app learns from your symptom patterns to provide personalized support during your treatment.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.